Navidea Biopharmaceuticals, Inc. (NAVB): Price and Financial Metrics

Navidea Biopharmaceuticals, Inc. (NAVB): $0.26

-0.01 (-2.22%)

POWR Rating

Component Grades













Add NAVB to Watchlist
Sign Up

Industry: Biotech



in industry

NAVB Stock Summary

  • NAVB has a higher market value than merely 1.92% of US stocks; more precisely, its current market capitalization is $7,682,925.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -7.11 for NAVIDEA BIOPHARMACEUTICALS INC; that's greater than it is for just 2.32% of US stocks.
  • Revenue growth over the past 12 months for NAVIDEA BIOPHARMACEUTICALS INC comes in at -76.59%, a number that bests only 1.92% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to NAVB, based on their financial statements, market capitalization, and price volatility, are VTVT, ACER, GEOS, ICPT, and ESPR.
  • NAVB's SEC filings can be seen here. And to visit NAVIDEA BIOPHARMACEUTICALS INC's official web site, go to

NAVB Valuation Summary

  • In comparison to the median Healthcare stock, NAVB's price/earnings ratio is 103.06% lower, now standing at -0.6.
  • Over the past 243 months, NAVB's EV/EBIT ratio has gone up 1.6.

Below are key valuation metrics over time for NAVB.

Stock Date P/S P/B P/E EV/EBIT
NAVB 2022-09-23 35.8 -1.7 -0.6 -0.7
NAVB 2022-09-22 35.8 -1.7 -0.6 -0.7
NAVB 2022-09-21 37.3 -1.8 -0.6 -0.7
NAVB 2022-09-20 38.7 -1.9 -0.7 -0.7
NAVB 2022-09-19 38.7 -1.9 -0.7 -0.7
NAVB 2022-09-16 41.2 -2.0 -0.7 -0.7

NAVB Growth Metrics

    Its 3 year cash and equivalents growth rate is now at -17.23%.
  • The 2 year net income to common stockholders growth rate now stands at -4.99%.
  • Its 4 year revenue growth rate is now at -96.63%.
Over the past 15 months, NAVB's revenue has gone down $678,222.

The table below shows NAVB's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 0.204256 -9.436224 -12.0767
2022-03-31 0.407776 -9.711727 -11.75128
2021-12-31 0.531513 -10.21815 -11.73093
2021-09-30 0.700416 -10.04659 -11.08244
2021-06-30 0.872423 -10.66532 -11.9495
2021-03-31 0.882478 -10.285 -11.67886

NAVB Stock Price Chart Interactive Chart >

Price chart for NAVB

NAVB Price/Volume Stats

Current price $0.26 52-week high $1.81
Prev. close $0.27 52-week low $0.23
Day low $0.26 Volume 26,647
Day high $0.28 Avg. volume 194,921
50-day MA $0.39 Dividend yield N/A
200-day MA $0.76 Market Cap 8.02M

Navidea Biopharmaceuticals, Inc. (NAVB) Company Bio

Navidea Biopharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of precision radiopharmaceutical diagnostics for diseases such as cancer.

NAVB Latest News Stream

Event/Time News Detail
Loading, please wait...

NAVB Latest Social Stream

Loading social stream, please wait...

View Full NAVB Social Stream

Latest NAVB News From Around the Web

Below are the latest news stories about NAVIDEA BIOPHARMACEUTICALS INC that investors may wish to consider to help them evaluate NAVB as an investment opportunity.

Navidea Biopharmaceuticals Appoints Joshua Wilson to the Board of Directors; Announces Dates Related to its 2022 Annual Meeting of Stockholders

DUBLIN, Ohio, September 30, 2022--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the appointment of Joshua ("Josh") Wilson to its Board of Directors, effective September 30, 2022, with a term ending concurrently with the Company’s 2024 annual stockholders’ meeting.

Yahoo | September 30, 2022

Navidea Biopharmaceuticals Announces Presentation of Results from its Two Phase 2B Clinical Trials in Rheumatoid Arthritis at Upcoming American College of Rheumatology Annual Meeting

DUBLIN, Ohio, September 15, 2022--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that the results from the Company’s completed NAV3-31 Phase 2B clinical study as well as the preliminary results of its ongoing NAV3-32 Phase 2B study have been accepted for presentation as posters at the Annual Meeting of the American College of Rheumatology ("ACR")

Yahoo | September 15, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

We're starting off Wednesday with an overview of the biggest pre-market stock movers this morning and the news moving those shares!

William White on InvestorPlace | September 14, 2022

Navidea Biopharmaceuticals, Inc. (NAVB) Q2 2022 Earnings Call Transcript

Navidea Biopharmaceuticals, Inc. (NAVB)

Q2 2022 Earnings Conference Call

September 08, 2022, 04:00 PM ET

Company Participants

Michael Rosol – CMO

Alex Cappello - Vice Chair

Erika Eves - VP, Finance & Administration

Conference Call Participants

Michael Okunewitch - Maxim Group

Fred Zaino - Keystone

Michael Okunewitch - Maxim Group



Greetings. Welcome to the Navidea Quarter Two 2022 Earnings Call and Business Update. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] And please note that this conference is being recorded....

SA Transcripts on Seeking Alpha | September 9, 2022

Edited Transcript of NAVB.A earnings conference call or presentation 8-Sep-22 8:00pm GMT

Q2 2022 Navidea Biopharmaceuticals Inc Earnings Call and Business Update

Yahoo | September 8, 2022

Read More 'NAVB' Stories Here

NAVB Price Returns

1-mo -18.75%
3-mo -61.76%
6-mo -66.67%
1-year -85.31%
3-year -61.82%
5-year -96.98%
YTD -74.00%
2021 -53.49%
2020 70.63%
2019 -37.00%
2018 -72.22%
2017 -43.75%

Continue Researching NAVB

Here are a few links from around the web to help you further your research on Navidea Biopharmaceuticals Inc's stock as an investment opportunity:

Navidea Biopharmaceuticals Inc (NAVB) Stock Price | Nasdaq
Navidea Biopharmaceuticals Inc (NAVB) Stock Quote, History and News - Yahoo Finance
Navidea Biopharmaceuticals Inc (NAVB) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9758 seconds.